Skip to main content

Branded

  • Watson to expand Salt Lake City manufacturing, R&D plant

    SALT LAKE CITY — Watson Pharmaceuticals plans to expand its manufacturing and research and development plant in Salt Lake City, the drug maker said.

    The $44 million expansion of the plant will include retrofitting about 20,000 sq. ft. of space and the construction of about 17,000 additional sq. ft. The expansion of the plant, which makes transdermal patches and topical gels, is expected to include the addition of about 300 new employees over the next three to five years.

  • AstraZeneca sells off Astra Tech to Dentsply

    WILMINGTON, Del. — AstraZeneca announced that it is selling its Astra Tech business to a professional dental products company in a cash transaction valued at about $1.8 billion.

    Dentsply will acquire Mölndal, Sweden-based Astra Tech, which focuses on dental and healthcare products, services and support. In 2010, Astra Tech recorded worldwide revenue of $535 million.

    AstraZeneca noted that the transaction is anticipated to be completed during the second half of 2011.

  • Endo completes acquisition of American Medical Systems

    CHADDS FORD, Pa. — Endo Pharmaceuticals has acquired a provider of devices and therapies for male and female pelvic health.

    Endo said its acquisition of American Medical Systems has boosted the drug maker's devices and services business segment, and the combination of AMS with Endo's existing platform will provide additional cost-effective solutions across the entire urology spectrum.

    The company announced its definitive agreement to acquire AMS in a cash transaction valued for approximately $2.9 billion.

  • Pfizer, Acura get FDA OK for Oxecta

    NEW YORK — The Food and Drug Administration has approved a medication designed to treat acute and chronic moderate to severe pain, where the use of an opioid analgesic is suitable.

    Pfizer and Acura Pharmaceuticals said that their drug Oxecta (oxycodone HCl, USP tablets) is the first tamper-resistant medication designed to deter abuse and misuse with Aversion technology, which is being licensed by Pfizer from Acura.

  • Q&A: A new drug for Type 2 diabetes — Wa'el Hashad, Boehringer Ingelheim

    Last month, the Food and Drug Administration approved Tradjenta (linagliptin), an oral Type 2 diabetes drug made by German drug maker Boehringer Ingelheim and Indianapolis-based Eli Lilly. The drug belongs to the class known as dipeptidyl peptidase-4 inhibitors, which also includes Merck’s Januvia (sitagliptin). With diabetes affecting some 26 million Americans and growing rapidly, Drug Store News spoke with Wa’el Hashad, BI’s VP cardiovascular and metabolic disorders marketing, about what the approval of Tradjenta means for the diabetes market.


  • Lilly, BI gear up to present data from studies of diabetes drugs

    RIDGEFIELD, Conn. — Just after the approval of their new treatment for Type 2 diabetes, Eli Lilly and Boehringer Ingelheim plan to present data in more than two dozen presentations at the American Diabetes Association Scientific Sessions starting this week.

    Lilly and BI, which recently launched the oral diabetes drug Tradjenta (linagliptin) will present data from studies of the drug, as well as studies on BI-10773, an investigational diabetes drug made by BI.

  • Abbott receives FDA approval for Lupron Depot

    ABBOTT PARK, Ill. — The Food and Drug Administration has approved a new formulation of an injectable drug made by Abbott for prostate cancer.

    Abbott announced Monday the approval of a 45-mg, six-month formulation of Lupron Depot (leuprolide acetate) for advanced prostate cancer. Previous formulations have allowed patients to receive the drug every month or every three or four months.

  • Specialty Rx, diabetes to drive drug trend

    The overall growth in drug spending for 2010 was 3.7%, according to the latest drug trend report by pharmacy benefit manager Medco Health Solutions. The lower increase 
was primarily due to higher rates of generic drug dispensing — more than 71% of drugs dispensed were generics. 


X
This ad will auto-close in 10 seconds